BIO3 Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.20 |
| 52 Week High | €31.60 |
| 52 Week Low | €24.70 |
| Beta | 0.24 |
| 11 Month Change | 2.26% |
| 3 Month Change | 7.94% |
| 1 Year Change | -13.38% |
| 33 Year Change | -30.96% |
| 5 Year Change | 28.61% |
| Change since IPO | 16.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -1.1% | 3.8% | -0.6% |
| 1Y | -13.4% | 6.0% | 2.5% |
Return vs Industry: BIO3 underperformed the Austrian Biotechs industry which returned 6% over the past year.
Return vs Market: BIO3 underperformed the Austrian Market which returned 2.5% over the past year.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: BIO3 has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: BIO3's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,464 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market cap | €1.36b |
| Earnings (TTM) | €68.50m |
| Revenue (TTM) | €707.00m |
15.8x
P/E Ratio1.5x
P/S RatioIs BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €707.00m |
| Cost of Revenue | €459.30m |
| Gross Profit | €247.70m |
| Other Expenses | €179.20m |
| Earnings | €68.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.73 |
| Gross Margin | 35.04% |
| Net Profit Margin | 9.69% |
| Debt/Equity Ratio | 116.4% |
How did BIO3 perform over the long term?
See historical performance and comparison